Dr. Angelos M. Stergiou: The SELLAS Life Sciences Group Team

Dr. Angelos M. Stergiou, MD is the Founder, Chief Executive Officer (CEO) and Vice Chairman of the SELLAS Life Sciences Group. Dr. Angelos Stergiou founded SELLAS Life Sciences with his friend and colleague, Dr. Miltos K. Sugiultzoglu, MD and, through their company, they partnered with Memorial Sloan Kettering Cancer Center and began furthering the development of the WT1 cancer vaccine.

Also within the company is the SVP, Chief Medical Officer, Nicholas Sarlos, MD, PhD, FACP; the Chief Regulatory Officer, Gregory M. Torre, PhD, JD; the Chief Operating Officer, Martin G. Baum; the Chief Financial Officer, William Pollett; the SVP and Head of Clinical Development, Anthony Williams, MBBS, Senior VP; the VP of Clinical Operations and Biostatistics, Laura M. Katz, MPH and the VP of Legal Affairs, David Moser.

To know more about the SELLAS Life Sciences Group, please checkout this link:  http://www.prnewswire.com/news-releases/sellas-life-sciences-announces-positive-interim-phase-ii-results-from-its-wt1-immunotherapeutic-anti-cancer-treatment-in-multiple-myeloma-patients-300343924.html

Advertisements
Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos M. Stergiou, MD, ScD h.c.: Shape the World with a Biotechnology Career

Dr. Angelos M. Stergiou, MD, ScD h.c. has always wanted to change the world and give back to humanity. Through SELLAS Life Sciences Group, he is doing just that. SELLAS Life Sciences Group is a biopharmaceutical company that is behind some of today’s most promising cancer treatments – such as the WT1 cancer vaccine – and they are in position to save lives of cancer patients around the world.

If you would like to join visionaries like Dr. Angelos Stergiou in changing the world, biotechnology might be the perfect career for you. Using breakthrough technologies, developing new drugs to help humanity and pushing science forward are just some of the many perks.

Interested? The information below will help you get started:

  • The education required for biotechnology careers varies, but most typically require a Bachelor’s degree in a related field such as biology or medicine, as a minimum and further doctoral degrees in Medicine, Science, Research as well as Business are of benefit.
  • Job Market and Salary. The demand for biotechnologists, as of 2016, is expected to increase significantly over the next decade. Salaries vary widely, based on position and education and can range from $60,000 to very high salaries depending on executive position and size of companies.

Never assume that you can’t join today’s prominent minds in changing the world. In Dr. Angelos M. Stergiou’s own words: “Keep dreaming and keep on going. Make your dreams a reality, and after difficult times, always get back up.”

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos Stergiou, MD, ScD h.c.: The WT1 Program

Dr. Angelos M. Stergiou, MD, is Founder, Vice Chairman and Chief Executive Officer of SELLAS Life Sciences Group, a biopharmaceutical company that is pioneering the cancer vaccination field. The one that’s receiving the most attention is the WT1 cancer vaccine, galinpepimut-S.

In the Phase 2 clinical trial of the WT1 cancer vaccine, Dr. Angelos M. Stergiou, MD, ScD h.c. and the team at SELLAS Life Sciences Group celebrated promising results. If findings continue to follow the current pattern, the WT1 cancer vaccine could begin saving lives in the near future.

  • The WT1 Vaccine. The National Cancer Institute has identified the WT1 antigen as the #1 target for immunotherapeutic treatment. This antigen is rarely found in healthy adult cells, but it is routinely found in cancerous tumors and even some cancer stem cells. By teaching the body to target the WT1 antigen, SELLAS Life Sciences Group’s vaccine effectively allows patients’ T cells to kill cancer from within.

The WT1 cancer vaccine could help fight as many as twenty types of cancer.

Also Checkout: http://www.slideshare.net/AngelosStergiou/angelos-stergiou-about-sellas-life-sciences-group

  • Study Results. In the Phase 2 clinical trial, the WT1 cancer vaccine improved patient survival rate and lengthened periods of remission when compared to the control group. Though the vaccine is not yet ready for public use, as of 2016, upcoming trials and research offer exciting possibilities.

As CEO of SELLAS Life Sciences Group, Dr. Angelos M. Stergiou, MD, ScD h.c. Has given numerous presentations speaking about SELLAS Life Sciences Group’s WT1 cancer vaccine and, in a 2016 interview, he described the possibility of it helping patients in the near future as “breathtaking.”

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos M. Stergiou, MD, ScD h.c.: Active Association Member

Dr. Angelos M. Stergiou, MD is the Vice Chairman of SELLAS Life Sciences Group and an active member of the American Academy of Physicians in Research, the World Medical Association, the Association of Clinical Research Professionals and is also a Fellow of the Royal Society of Medicine in the UK.


Get Connected with Dr. Angelos Stergiou through social channel:

https://twitter.com/drstergiou

https://plus.google.com/116965580440240268259

https://www.facebook.com/Angelos-Stergiou-1813027965638555

 

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos M. Stergiou: Why SELLAS Life Sciences Group is in the News

Dr. Angelos M. Stergiou, MD is the Founder, Chief Executive Officer and Vice Chairman of SELLAS Life Sciences Group.  Angelos Stergiou and his company are changing medicine and science as we know it, and in doing so, they’re potentially saving countless lives.

As the WT1 cancer vaccine trials gain momentum and exposure, Dr. Angelos Stergiou and his team are receiving media attention and international acclaim.

The points below just scratch the surface of this fascinating company that’s pioneering the field of cancer vaccination:

  • Company Overview. SELLAS Life Sciences Group is a biopharmaceutical company that was founded in 2012 by Dr. Stergiou and his colleague, Dr. Miltos K. Sugiultzoglu, MD. It is centered around developing novel cancer therapeutics to save lives and to push cancer vaccination to the next level.

When speaking about the company, Dr. Stergiou was quoted in a 2016 interview stating: “I have always wanted to give back to humanity, and without clinical research, discovery and drug development, we would not have new drugs. The biotechnology sector is a passion of mine. It combines medicine, research and business, and I truly love doing every day.” He continued, saying: “The fact that we are currently developing a cancer vaccine with Memorial Sloan Kettering Cancer Center is very exciting and gets me going.”

  • WT1 Cancer Vaccine. The WT1 cancer vaccine is the most promising oncology product within SELLAS Life Sciences Group. It is named for the WT1 antigen, found in many cancers and few healthy adult cells. It teaches the immune system to seek and destroy the antigen, creating an effective internal response against cancer and recurring tumors. It is among Dr. Stergiou’s biggest accomplishments.

In a recent interview, he stated “We are entering pivotal Phase 3 studies [for the WT1 cancer vaccine] and have an exciting path ahead of us.” In further discussions about the WT1 cancer vaccine, Dr. Angelos Stergiou was quoted saying “The thirst to get to the finish line and get [the WT1 cancer vaccine] approved, so we can potentially save lives, is breathtaking.”

To follow the progression of SELLAS Life Sciences Group and Dr. Angelos M. Stergiou’s team, head to Sellas Life Sciences and keep an eye on happenings around the website. Alternately, stay current with oncology news and you’re sure to see breakthrough trials in the near future.

Also visit: http://sellaslifesciences.com/biopharma/news/

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos Stergiou: Is a Pharmaceutical Career Right for You?

Dr. Angelos M. Stergiou, MD is the Founder, Vice Chairman and CEO of the biopharmaceutical company known as SELLAS Life Sciences Group. In Dr. Stergiou’s own words, “without clinical research, discovery and drug development, we would not have new drugs.” This simple fact has sparked modern interest in pharmaceutical careers.

If the accomplishments and words of pharma experts like Dr. Angelos Stergiou inspire you, it might be time to look further into the field. The information below is a good place to begin:

  • Growing Industry. New medicine is something that the world will always need. The pharmaceutical industry has a consistently-positive industry growth projection and ever-increasing job opportunities for skilled professionals. Furthermore, some countries have trouble filling pharmaceutical positions to capacity, meaning that finding a position in pharma can be easier than finding one in other fields of study.
  • Well-Paying Work. Pharmaceutical positions are well-paying in most countries, typically averaging around thirty-percent higher than national median salary. Though high salaries are always attractive, the projected increase in pharmaceutical pay is an even more attractive prospect.
  • Steady Employment. Medicine is always needed, and pharmaceutical professionals do not suffer the same ups and downs as those in other careers often do. In times of crisis, even, pharmaceuticals are required, and pharma employees are valued.

After nearly 15 years of experience, Dr. Angelos Stergiou, MD is still learning new things, loving his job and pushing his field further. Speaking with respected educational institutions is the first step to joining these professionals in changing the world, improving lives and, hopefully, saving those suffering from disease.

Also read: https://angelosstergiou.wordpress.com/2016/11/03/dr-angelos-stergiou-md-scd-h-c-international-upbringing/

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos M. Stergiou, MD, ScD h.c.: International Upbringing

Dr. Angelos M. Stergiou, MD, ScD h.c. is the Vice Chairman and CEO of SELLAS Life Sciences Group and an international professional. Angelos Stergiou was born and raised in Germany, where his family fought to succeed in the struggling economy. At the age of sixteen, Dr. Angelos moved to the United States to complete high school as an exchange student due to his very good grades in Germany and to eventually begin his university education in the USA.

 

Visit here http://sellaslifesciences.com/management/ to view more detail about Dr. Angelos M. Stergiou.

 

 

Posted in Angelos Stergiou | Tagged ,